RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study

BACKGROUND: The monoclonal antibody, palivizumab is licensed for use in high-risk infants to prevent severe illness caused by respiratory syncytial virus (RSV). The level of its use and compliance with current jurisdictional guidelines which were amended in 2010, is unknown. We determined the level...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ruomei, Fathima, Parveen, Strunk, Tobias, de Klerk, Nicholas, Snelling, Thomas L., Richmond, Peter C., Keil, Anthony D., Moore, Hannah C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584096/
https://www.ncbi.nlm.nih.gov/pubmed/33092566
http://dx.doi.org/10.1186/s12887-020-02390-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584096/
https://www.ncbi.nlm.nih.gov/pubmed/33092566
http://dx.doi.org/10.1186/s12887-020-02390-5

Ejemplares similares